BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Jair Bar, S. Keren et al.|Journal of Thoracic Oncology|2018Cited by 220
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Nir Peled, Mor Moskovitz et al.|Lung Cancer|2017Cited by 104
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Nir Peled, Elias Bshara et al.|Lung Cancer|2018Cited by 75
Crizotinib Restored Pembrolizumab Response in Advanced Non-Small Cell Lung CancerLaila C. Roisman|European Journal of Respiratory Medicine|2022Cited by 0